Filing Details

Accession Number:
0000769993-14-000533
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-08-14 17:27:14
Reporting Period:
2014-08-12
Filing Date:
2014-08-14
Accepted Time:
2014-08-14 17:27:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1492674 T2 Biosystems Inc. TTOO Surgical & Medical Instruments & Apparatus (3841) 204827488
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1589295 Mbd Advisors, L.l.c. 200 West Street
New York NY 10282
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-08-12 2,548,150 $0.00 2,548,150 No 4 C Indirect See footnotes
Common Stock Acquisiton 2014-08-12 909,090 $11.00 3,457,240 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnotes
No 4 P Indirect See footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series E Preferred Stock Disposition 2014-08-12 4,331,858 $0.00 2,548,150 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
Footnotes
  1. This statement is being filed by The Goldman Sachs Group, Inc. ("GS Group"), Goldman, Sachs & Co. ("Goldman Sachs"), MBD 2013, L.P. ("MBD"), MBD 2013 Offshore, L.P. ("MBD Offshore"), MBD 2013 Holdings, L.P. ("MBD Holdings"), Broad Street Principal Investments, L.L.C. ("Broad Street"), Bridge Street 2013, L.P. ("Bridge Street"), Bridge Street 2013 Offshore, L.P. ("Bridge Street Offshore"), and Bridge Street 2013 Holdings, L.P. ("Bridge Street Holdings" and, together with MBD, MBD Offshore, MBD Holdings, Broad Street, Bridge Street, and Bridge Street Offshore, the "GS Funds"), MBD Advisors, L.L.C. ("MBD Advisors") and Bridge Street Opportunity Advisors, L.L.C. ("Bridge Street Advisors" and, together with GS Group, Goldman Sachs, the GS Funds and MBD Advisors, the "Reporting Persons").
  2. Due to the electronic system's limitation of 10 Reporting Persons per joint filing, this statement is being filed in duplicate.
  3. In connection with the closing of the initial public offering (the "IPO") of Common Stock, par value $0.001 per share (the "Common Stock") of T2 Biosystems, Inc. (the "Company"), which occurred on August 12, 2014, 4,331,858 shares of the Company's Series E Preferred Stock (the "Preferred Stock"), beneficially owned directly by certain of the GS Funds, and which may be deemed to have been beneficially owned indirectly by GS Group and Goldman Sachs, automatically converted into 2,548,150 shares of the Company's Common Stock. The Preferred Stock was immediately exercisable and had no expiration date.
  4. In connection with the closing of the IPO on August 12, 2014, 3,638,761 shares of Preferred Stock beneficially owned directly by Broad Street automatically converted into 2,140,447 shares of Common Stock. 537,150 shares of Preferred Stock beneficially owned directly by Bridge Street Holdings, which may be deemed to have been beneficially owned indirectly by each of Bridge Street, Bridge Street Offshore and Bridge Street Advisors by reason of the direct beneficial ownership of Preferred Stock by Bridge Street Holdings, automatically converted into 315,970 shares of Common Stock. 155,947 shares of Preferred Stock beneficially owned directly by MBD Holdings, which may be deemed to have been beneficially owned indirectly by MBD, MBD Offshore and MBD Advisors by reason of the direct beneficial ownership of Preferred Stock by MBD Holdings, automatically converted into 91,733 shares of Common Stock.
  5. On August 12, 2014, in connection with the closing of the IPO, certain of the GS Funds purchased an aggregate of 909,090 shares of Common Stock at the IPO price of $11.00 per share of Common Stock. Broad Street purchased 763,636 shares of Common Stock, Bridge Street Holdings purchased 112,727 shares of Common Stock and MBD Holdings purchased 32,727 shares of Common Stock.
  6. GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 3,457,240 shares of Common Stock by reason of the direct beneficial ownership of Common Stock by certain of the GS Funds because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs is a wholly owned subsidiary of GS Group. Goldman Sachs is the investment manager of certain of the GS Funds.
  7. Broad Street beneficially owns directly 2,904,083 shares of Common Stock. Bridge Street Holdings beneficially owns directly 428,697 shares of Common Stock. Bridge Street, Bridge Street Offshore and Bridge Street Advisors may each be deemed to beneficially own indirectly 428,697 shares of Common Stock by reason of the direct beneficial ownership of Common Stock by Bridge Street Holdings. MBD Holdings beneficially owns directly 124,460 shares of Common Stock. MBD, MBD Offshore and MBD Advisors may each be deemed to beneficially own indirectly 124,460 shares of Common Stock by reason of the direct beneficial ownership of Common Stock by MBD Holdings.
  8. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.